Vaxart (NASDAQ:VXRT) Stock Price Up 8.6%

Vaxart Inc (NASDAQ:VXRT)’s share price rose 8.6% during trading on Monday . The stock traded as high as $0.39 and last traded at $0.38, approximately 1,050,200 shares changed hands during mid-day trading. An increase of 78% from the average daily volume of 588,833 shares. The stock had previously closed at $0.35.

VXRT has been the topic of several analyst reports. ValuEngine downgraded Vaxart from a “buy” rating to a “hold” rating in a report on Monday, September 30th. HC Wainwright set a $2.00 target price on Vaxart and gave the stock a “buy” rating in a research report on Wednesday, August 21st. Brookline Capital Management assumed coverage on Vaxart in a research report on Thursday, August 15th. They set a “buy” rating and a $6.00 target price for the company. Finally, Zacks Investment Research upgraded Vaxart from a “hold” rating to a “buy” rating and set a $0.75 target price for the company in a research report on Friday, August 30th.

The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.29. The firm has a 50-day moving average of $0.55 and a 200-day moving average of $0.77. The stock has a market cap of $5.92 million, a PE ratio of -0.14 and a beta of 0.57.

Vaxart (NASDAQ:VXRT) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.11. Vaxart had a negative return on equity of 131.05% and a negative net margin of 244.38%. The firm had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $1.10 million. Equities analysts forecast that Vaxart Inc will post -1.45 EPS for the current fiscal year.

In other news, insider Wouter Latour purchased 166,667 shares of the business’s stock in a transaction on Monday, September 30th. The stock was acquired at an average price of $0.30 per share, for a total transaction of $50,000.10. Also, major shareholder Armistice Capital Master Fund purchased 564,000 shares of the business’s stock in a transaction on Monday, October 7th. The shares were purchased at an average price of $0.36 per share, with a total value of $203,040.00. Insiders have purchased 8,500,000 shares of company stock valued at $2,532,307 in the last quarter. 7.30% of the stock is currently owned by company insiders.

An institutional investor recently raised its position in Vaxart stock. Renaissance Technologies LLC grew its holdings in shares of Vaxart Inc (NASDAQ:VXRT) by 120.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 739,653 shares of the biotechnology company’s stock after acquiring an additional 404,883 shares during the quarter. Renaissance Technologies LLC owned about 4.69% of Vaxart worth $496,000 at the end of the most recent quarter. 12.51% of the stock is owned by hedge funds and other institutional investors.

Vaxart Company Profile (NASDAQ:VXRT)

Vaxart, Inc, a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus.

Further Reading: What is the formula for calculating total return?

Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.